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Regulation of' kallikrein and renin release by the isolated perfused rat
kidney. Rat kidneys perfused in vitro released kallikrein in urine, and
renin and kallikrein in the perfusate. The kallikrein was characterized
by its kininogenase activity and released bradykinin from bovine and
dog substrates. Inactive trypsin activatable kallikrein was present in
both perfusate and urine. Kallikrein secretion in urine was influenced
by changes in perfusion pressure (PP). Raising the PP strikingly
increased urinary kallikrein and lowering PP reduced it. Urinary water
and electrolyte output were augmented to the same extent by furose-
mide and mannitol administration as by raising the PP, but neither drug
affected kallikrein. Isoproterenol stimulated the release of renin but not
kallikrein. Stopping the oxygen supply to the perfusate suppressed
kallikrein secretion in urine and renin release in the perfusate. The
kidneys released ten times less kallikrein in the perfusate than in urine,
and perfusate kallikrein was not influenced by changes in PP. It is
concluded that in this model, changes in PP and/or renal blood flow
and/or oxygen supply regulate kallikrein secretion in urine, but that this
secretion is unaffected by changes in urinary output. We also conclude
that kallikrein release in urine and renin release in perfusate are
regulated simultaneously by renal hemodynamic changes but are not
affected concomitant by beta-adrenergic stimulation or changes in distal
urine composition.
Regulation de Ia secretion de kallicréine et de renine par le rein de rat
isole perfuse. Le rein de rat isolé perfuse sCcréte de Ia kallicréine dans
l'urine, de Ia rénine et de Ia kallicréine dans Ic perfusat. La kallicrCine
rénale libére de Ia bradykinine par l'hydrolyse du kininogene de boeuf
et de chien. L'activité kallicréine est quantifiée par Ia mesure de Ia
bradykinine formée. On retrouve de Ia kallicréine inactive, activable
par Ia trypsine, dans le perfusat et dans l'urine. La sécrétion de
kallicréine dans l'urine est regulée par les changements de pression de
perfusion (PP) du rein. Une augmentation de PP stimule puissamment la
liberation de kallicréine et une diminution de PP réduit cette liberation.
Le furosémide et le mannitol produisent Ia méme augmentation de
diurése que l'augmentation de PP, mais n'influencent pas Ia sécrétion
de kallicrCine. L'isoproterenol stimule Ia liberation de rénine, mais pas
celle de kallicréine. L'arrêt de l'apport d'oxygène dans Ic perfusat
supprime Ia sécrétion de kallicrCine dans l'urine et celle de rénine dans
Ic perfusat. Le rein libére dix fois moms de kallicréine dans le perfusat
que dans l'urine. La liberation de kallicréine dans Ic perfusat n'est pas
influencCe par les changements de PP. En conclusion, les changements
de PP et/ou de debit sanguin renal et/ou d'apport en oxygene regulent Ia
sCcrétion urinaire de kallicrCine par le rein perfuse isolé. Les variations
de volume et de composition de l'urine sont sans effets sur cette
sCcrétion. Par ailleurs, La sécrétion de kallicréine dans l'urine et celle de
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rénine dans Ic perfusat sont regulees simultanément lors des change-
ments de l'hemodynamique intrarénale mais pas lors d'une stimulation
beta-adrCnergique ou lors des changements de composition de l'urine
distale qui influencent La rCnine mais pas Ia kallicréine.
The renal kallikrein-kinin system may be involved in the
control of salt and water excretion [1, 2] and of blood pressure
[3, 4]. Previous studies have indeed shown that excretion of
active kallikrein in urine is influenced by changes in the sodium
balance [5—7] and may be regulated by the mineralocorticoid
level in blood [4, 5, 8]. Furthermore, urinary kallikrein activity
alters in experimental and human hypertension [3, 4, 9].
However, the role of kallikrein in renal function is not well
understood. If secreted in blood, kallikrein may release kinins
from kininogen and induce renal vasodilatation. There is how-
ever no direct evidence for in vivo release of renal kallikrein
into the capillary or venous blood. On the other hand, the
physiological role of the kallikrein synthesized in the distal
tubule, bound to the tubule surface, and secreted in urine, is
unknown.
Renin is also synthesized by the kidney [101 and secreted in
blood; it releases angiotensin and regulates the renal blood flow
[11]. The renin-angiotensin system is linked to the kallikrein-
kinin system: The angiotensin converting enzyme splits angio-
tensin I (Al) into angiotensin II and inactivates bradykinin (BK)
[12]. There is, however, no direct evidence that the renin-
angiotensin and the kallikrein-kinin systems act together to
regulate renal function. It seems likely that renal hemodynamic
changes can affect kallikrein as well as renin secretion. Con-
stricting the renal artery, a well known stimulus of renin
secretion, reduces urinary kallikrein excretion in parallel with
the decrease in renal artery pressure [131. It is not known if
these variations in renal perfusion affect kallikrein secretion
directly or indirectly by inducing changes in the renal excretory
function. Furthermore, it is not established if other different
physiological events able to regulate renin release, such as
changes in urine composition or in sympathetic activity, simul-
taneously affect the secretion of kallikrein in blood or urine by
the kidney.
During the past few years, the isolated blood-free perfused
rat kidney has proven to be a useful tool for studying the
mechanisms of renin release [14—16]. It has also been used by
Roblero et al [17] who showed that the isolated rat kidney
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elaborates a high level of kallikrein activity in perfusate and
urine. The present study was therefore designed to document,
in this model, the release of kallikrein in urine and perfusate,
and to characterize the regulation of kallikrein secretion during
changes in renin release. For this purpose, we examined the
effects of changes in perfusion pressure and renal blood flow, or
of changes in urinary output of water and electrolytes, as well
as the effects of beta-adrenergic stimulation.
Methods
Kidney perfusion. Male Wistar rats of 300 to 400 g, fed a
regular sodium diet (170 mEq Na/kg of food) and allowed to
drink tap water ad libitum, were used. The procedure used to
remove and perfuse the rat kidney has been described in detail
previously [18]. The right kidney was isolated and placed in a
perfusion chamber without stopping the renal perfusion. The
kidney was perfused at 37°C in a closed circuit with 80 ml of
Krebs-Ringer bicarbonate pH 7.4 containing 60 g/liter bovine
serum albumin (Cohn's fraction V, Sigma Chemical Company,
St. Louis, Missouri) and 5.5 m glucose. The perfusate was
aerated continuously with 021C02 (95:5) except in the oxygen-
deprivation experiments. Perfusion pressure (PP) was deter-
mined by perfusate outflow from the pump and the resistance of
the shunt circuit introduced in the perfusion system [18]. The
changes in perfusate flow were monitored by a flow meter
(Ono, Tokyo, Japan). In every experiment, the kidney was
allowed to equilibrate in the perfusion system for 20 mm, during
which time the PP was kept at 80 mm Hg. The kidney was then
perfused at the chosen PP for an additional 90 mm. Urine was
collected every 15 mm for the measurement of urinary volume
(UV), sodium, potassium, and kallikrein and renin activity.
Samples were taken from the perfusate at 0, 30, 60, and 90 mm
after the equilibration period for measurement of kallikrein and
renin activity. The glomerular filtration rate (GFR) was deter-
mined by the clearance rate of the tritiated polyethylene glycol
(10 MCi/liter, New England Nuclear Corporation, Boston, Mas-
sachusetts) added to the perfusate [18].
Kidneys were perfused under the following conditions: In
controls (N = 11), the PP was kept at 80 mm Hg for 90 mm. In
experimental kidneys, (1) to define the effects of changes in PP,
PP was kept at 80 mm Hg for 30 mm and then raised to 110 mm
Hg (N = 6) or lowered to 60 mm Hg (N = 6), and maintained at
this level for another 60 mm. (2) Effects of diuretic agents were
studied by adding either mannitol (45 mrvi, N = 6) or furosemide
(100 LM, N = 6) to the perfusate after 30 mm of perfusion. (3)
Effects of beta-adrenergic stimulation (N =6) were determined
by adding isoproterenol (Isuprelx, 50 nM) after 30 mm of
perfusion. This concentration of the drug was previously shown
to increase renin release by 350% in this model [16]. (4) Effects
of oxygen-deprivation (N = 6) were observed after 30 mm of
perfusion when the oxygen supply to the perfusate was discon-
tinued. The perfusate was aerated with N2/C02 (95:5) for
another 60 mm. During the experiments concerning diuretics,
isoproterenol and oxygen-deprivation, PP was kept constant at
80 mm Hg. All drugs were added to the perfusate every 15 mm
during the 60 mm of the experiment.
Enzymatic assays. Renin assay. The renin concentration was
measured by radioimmunoassay (RIA) of the Al produced by
incubation with an excess of rat renin substrate [19]. It was
expressed in nanograms of Al generated per hour of incubation
per milliliter of perfusate or urine (ngAI m1' hr'). Since
kidneys were perfused in a closed circuit, the renin found in the
perfusate constituted the total amount released during the
experimental periods. The rate of renin secretion was calculat-
ed from the changes with time in the renin concentration. To
allow comparison with previous studies [16], it was expressed
in micrograms of A! generated per hour of incubation by the
enzyme released within I mm (/Lg A1 hr' min). Urinary
renin excretion was also calculated. It was expressed in micro-
grams of Al generated per hour of incubation by the total renin
present in each urinary sample (jig Al hr').
Kallikrein assay. Kallikrein activity was measured by its
kininogenase activity on bovine or dog substrate, as previously
described [20]. The kinins generated were assayed by RIA. To
determine kallikrein activity in urine, 2 to 25 l of urine were
incubated with either 15 mg of bovine substrate or 15 mg of dog
substrate in a total volume of 0.5 ml at pH 8.5 and 37°C for 60
mm. To determine the kallikrein activity in the perfusate, 100 sl
of perfusate were incubated under the same conditions. Howev-
er, before perfusion of the kidney, a small amount of kinin-like
immunoreactive material was found in the fresh perfusion fluid
which contains Cohn's fraction V from bovine plasma. This
material averaged 3.7 ng of BK equivalent per milliliter and was
not eliminated by dialysis. When incubated for 120 mm in the
presence of bovine or dog substrate, the fresh perfusion fluid
did not produce additional immunoreactive material, and there-
fore, it contained no kallikrein activity. After perfusion of the
kidney, the amounts of kinins produced from the bovine
substrate by the perfusion fluid was 6 to 50 ng BK per milliliter,
and the value of the immunoreactive material in the fluid before
perfusion had therefore to be subtracted from this quantity.
Consequently, whenever kallikrein activity was determined in
the perfusates, the enzyme activity was assayed both in the
absence and presence of 10,000 U/mi of aprotinin (Iniproi®).
The difference in the amount of kinins after incubation with and
without aprotinin was taken as the amount of kaliikrein activity
released during the perfusion. When 50 and 100 d of fresh
perfusate were preincubated for 60 mm at 37°C with 10 pi of
urine, the amount of kinin generated by urine was unchanged.
This shows the absence of kailikrein inhibitor in the perfusion
fluid.
Kallikrein activity in the perfusate was expressed in nano-
grams of BK per milliliter of perfusate per minute of incubation
(ng BK mi' min'). Urinary kallikrein secretion was calcu-
lated for each urine sample and expressed in nanograms of BK
generated per minute of incubation by the total enzyme present
in the sample (ng BK min). Kaliikrein secretion in the
perfusate was expressed in nanograms of BK generated for I
mm of incubation by the total kaliikrein released into the
perfusate (ng BK min).
Measurement of kallikrein activated by trypsin. The effect of
trypsin on kaiiikrein activity was tested as follows: 1 g trypsin
(Sigma Chemical Company) was added to 10 1.d of urine or to
100 jd of perfusate in 10 s1 of 0.2 M Tris pH 8.0 buffer.
Incubation was proceeded at 25°C for 20 mm, and the reaction
was then stopped by adding 20 g lima bean trypsin inhibitor
(Sigma Chemical Company). This procedure has been shown to
increase kaiiikrein activity significantly in human urine [211.
Kallikrein activity was measured as described above with and
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Table 1. Functional parameters of the isolated perfused rat kidney under different experimental conditions
Na
Groupa
Period
mm
PP
mmHg
RPF
m1min
GFR
mlmin UVj.lmin UNaVp.Eqmin reabsorption%
Control (11) 0 to 30
30 to 90
80 0.4
80 0.3
15.6 0.9
17.0 0.8
0.428 0.066
0.413 0.052
33.0 5.7
50.6 7.2
2.80 0.44
3.45 0.4!
95 I
94 I
High PP (6) 0 to 30
30 to 90
80 0.3
107 0.9
16.2 1.2
22.6 1.7C
0.409 0.077
0.639 0.078"
36.4 7.6
142.0 23.5C
2.81 0.96
11.48 1.56c
95 1
86 1'
Low PP (6) 0 to 30
30 to 90
80 0.4
60 0.5
16.1 0.7
14.5 0.6b
0.424 0.055
0.144 0.027C
36.7 6.9
15.1 3.1'
3.33 0.56
1.12 0.30'
94 I
96 I
Mannitol (6) 0 to 30
30 to 90
80 0.3
80 0.3
15.8 1.1
16.9 0.9
0.344 0.042
0.232 0.027b
32.3 7.1
120.8 15.2'
3.49 0.89
10.15 0.95'
93 1
74 4'
Furosemide (6) 0 to 30
30 to 90
80 0.3
80 0.3
15.2 1.2
15.8 1.5
0.387 0.028
0.275 0.014
38.4 7.2
100.8 14.6'
3.11 0.78
10.88 1.12'
94 1
72 4'
Isoproterenol (6) 0 to 30
30 to 90
80 0.3
80 0.3
16.2 0.7
17.0 0.7
0.406 0.058
0.399 0.030
53.0 12.0
71.5 8.1
3.94 1.12
4.59 1.32
93 2
90 2
Oxygen-deprived (6) 0 to 30
30 to 60
60 to 90
80 0.5
81 0.5
80 0.4
16.2 0.8
15.4 1.0
16.4 0.8
0.441 0.073
0.181 0.017'
0.026 0.004'
29.0 6.8
50.2 11.4
10.3 2.6'
3.05 0.79
6.17 1.27"
2.08 0.21
95 I
70 4'
29 5'
a Numbers in parentheses are the numbers of experiments. For oxygen-deprivation experiments three periods were considered: 0 to 30, 30 to 60,
and 60 to 90 mm.
"P < 0.05.
'P < 0.01, compared to control values.
without trypsin treatment. The ratios of total to active kallikrein
and of inactive to total kallikrein were calculated.
Identification of the kinin generated by rat renal kallikrein
secreted in urine and perfusate. The kinins generated by the
urine and the perfusate before and after trypsin treatment were
characterized by chromatography on a CM-cellulose column
according to Moriwaki, Fujimori, and Toyono [22]. Urine or
perfusate was incubated with kininogen as described above,
and the kinins generated were dissolved in 1 ml of 0.05 M
ammonium acetate, pH 6.5. The sample was then applied to a
0.9 x 16 cm CM-cellulose column equilibrated with 0.05 M
ammonium acetate, pH 6.5. The kinins were eluted with a linear
gradient from 0.05 to 0.4 M of ammonium acetate and quantified
by the RIA. In the control experiments, 10 ng of lysyl-
bradykinin (LBK) were incubated for 60 mm with either 10 pi of
urine or 100 d of perfusate together with 15 mg of substrate to
rule out any possible conversion of LBK into BK during
incubation [20]. The peptides were then chromatographed on
the CM-cellulose column, and two peaks were observed corre-
sponding to the BK generated and the LBK added (recov-
ery:65%). This demonstrated that, under our experimental
conditions, LBK was not converted into BK.
Other parameters determined. Urinary volume was estimat-
ed gravimetrically. Sodium and potassium in the perfusate and
urine were measured by flame photometer (Klina, Beckman
Instruments, Fullerton, California).
Results are expressed as means SEM. Analysis of variance
was used for statistical analysis.
Results
Functional parameters of the perfused kidney. The functional
parameters of the isolated perfused kidney during the different
perfusion procedures are shown in Table 1. Since any changes
in these procedures were always made after 30 mm of perfu-
sion, two periods were considered: 0 to 30 mm (control period)
and 30 to 90 mm (experimental period).
Raising the PP significantly increased the renal perfusate flow
(RPF), GFR, UV, and sodium excretion (UNaV) and significant-
ly reduced sodium reabsorption. When the PP was lowered, the
opposite changes occurred. Increases in filtered sodium load
were accompanied by a parallel decrease in sodium reabsorp-
tion. Mannitol and furosemide administration produced the
same increment in UV and UNaV as raising the PP (Table 1).
They did not change RPF and slightly diminished GFR as
previously reported [23]. Isoproterenol injection did not change
any of the physiological parameters significantly as we reported
previously [16]. During oxygen-deprivation both GFR and
sodium reabsorption fell drastically, but there was a time-
dependent change in UNaV. Since the initial decrease in tubular
reabsorption of sodium was larger than the decrease in the
filtered load of sodium, sodium excretion in urine rose. Subse-
quently, GFR fell to less than 10% of the control value and
despite a further decrease in sodium reabsorption, UNaV fell
too.
Kallikrein and renin release under basal conditions. The data
presented in Figures 1 to 3 and Tables 2 and 3 are obtained with
the use of bovine kininogen as the substrate for the measure-
ment of kallikrein activity. The cumulative secretion of kalli-
krein and renin in urine and perfusate during the 90-mm
perfusion under basal conditions is shown in Figure 1. More
than 90% of the active kallikrein released by the perfused
kidney was found in the urine and less than 10% in the
perfusate. Urinary secretion of kallikrein decreased with time
(Fig. 2). It usually reached a plateau after 30 mm of perfusion
and remained constant for the next 60 mm. The changes in PP
and oxygen supply and the effects of the drugs, therefore, were
studied after 30 mm of perfusion. In the perfusate, kallikrein
activity rose progressively with time during the 90-mm perfu-
sion from 0.04 0.01 ng BK• mY' mint to 0.09 0.01 ng
BK m11 min (N = 11). When dog kininogen was used
instead of bovine kininogen, more kinins were produced by rat
kallikrein, as previously reported [20]. Kallikrein activity in the
perfusate was then 0.24 0.09 ng BK ml min at the end
oftheequilibrationperiodand0.74 0.l2ngBK ml min
at 90 mm of perfusion (N = 5, P < 0.01).
Renin was secreted in the perfusate (Fig. 1) and the rate of
renin secretion increased slightly but not significantly with time
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(Fig. 2). A small amount of renin activity was found in urine
(Fig. 1). It gradually increased with time concomitant with the
rise in the renin concentration in the perfusate. This probably
reflects the excretion in urine of filtered renin not inactivated by
the tubules.
Regulation of kallikrein and renin secretion. Figure 2 shows
the effect of changing the PP on urinary kallikrein secretion and
on the rate of renin secretion in the perfusate. When the PP was
raised to 110 mm Hg, an immediate threefold increase in
kallikrein release in urine was observed. Although the PP was
kept at 110 mm Hg, kallikrein secretion fell to basal control
values within 15 mm. When the PP was lowered to 60 mm Hg,
kallikrein secretion in urine was almost suppressed for the
duration of the experiment. Since the rise in PP also increased
UV and UNaV, the effect on urinary kallikrein secretion of a
similar increase in UV and UNaV caused by diuretics was
studied at a constant PP of 80 mm Hg (Table 1 and Fig. 3).
Mannitol and furosemide did not significantly change urinary
kallikrein secretion (Table 2 and Fig. 3). Beta-adrenergic stimu-
lation by isoproterenol had no effect on kallikrein secretion in
urine (Table 2). In the absence of oxygen urinary kallikrein
secretion fell immediately and was almost completely sup-
pressed between 45 and 90 mm of perfusion (Table 2).
In the perfusate, no change in kallikrein secretion was
observed when PP was altered (Table 2). Kallikrein release into
Time, minutes
Fig. 2. Effects of changes in perfusion pressure on urinary kallikrein and
perfusate renin secretion. Ordinate represents the total kallikrein
secretion or rate of renin secretion. Arrows indicate a change in the
perfusion pressure: * P < 0.05, ** P < 0.01 compared to control values.
Symbols are: control, I—•; high PP, AA; low PP, •-'-•.
the perfusate did not change during mannitol, furosemide, or
isoproterenol administration. During oxygen-deprivation, kalli-
krein activity in the perfusate rose significantly (Table 2),
During the changes in PP, the variations in the amount of
renin released into the perfusate were the opposite to those
which occurred for kallikrein secretion in urine, that is, the rate
of renin release declined when the PP was increased and rose
when it was reduced. Renin release was reduced by mannitol
and enhanced by furosemide. Isoproterenol strikingly stimulat-
ed renin release into the perfusate, whereas renin release in the
perfusate was significantly reduced by oxygen-deprivation (Ta-
ble 4).
Urinary renin excretion increased significantly during isopro-
terenol and furosemide administration (Table 4) concomitant
with the increase in the renin concentration in the perfusate.
Renin excretion in urine rose when the PP was raised and
decreased when it was lowered. These changes were the
opposite to those occurring for renin release in the perfusate,
but corresponded to the changes in GFR. Renin excretion was
lower during anoxia than during the control period, because
both the GFR and renin concentration in the perfusate de-
creased. The ratio of the amount of renin excreted in urine to
the amount of renin released in the perfusate was calculated.
Between 30 and 90 mm of perfusion, it was 5.2 0.5% in
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Fig. 1. Comparison of kallikrein and renin release in perfusate and
urine. The figure shows the cumulative release of active kallikrein and
renin during 90 mm of perfusion at a constant pressure of 80 mm Hg.
White column represents perfusate; black column, urine; ordinate, total
amount of kallikrein or renin released.
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Table 2. Secretion of active kallikrein in perfusate and urine for the
last 60 mm of perfusiona
Perfusate Urine
Control (11) 2.18 0.47 33.08 3.98
High PP (6) 1.35 0.32 71.27 5.17b
Low PP (6) 2.10 0.77 6.93 l.09b
Mannitol (6) 2.68 0.60 24.07 4.47
Furosemide (6) 3.86 1.46 40.50 5.27
Isoproterenol (6) 1.75 0.60 35.03 8.87
Oxygen-deprived (6) 12.98 3.27b 9.42 0.92b
Data are expressed in ng BK min' (see Results). The numbers in
parentheses are the numbers of experiments.
b p < 0.01, compared to control values.
control kidneys. When the PP was raised to 110 mm Hg, GFR
rose by 56% and the percentage of renin excreted increased
sixfold to 33.8 5.9% (P < 0.01). When the PP was lowered to
60 mm Hg, GFR fell by 66%, and the percentage of excreted
renin fell to 1.4 0.2% (P < 0.01). Isoproterenol, which had no
significant effect on GFR, slightly reduced the percentage of
renin excreted (3.7 0.3, P < 0.05). Furosemide and mannitol
did not significantly affect the percentage of renin excreted (5.7
1.2 and 4.5 0.4, respectively). During oxygen-deprivation,
there was no significant change in the percentage of renin
excreted (5.8 2.4%) despite the drastic reduction in GFR.
Measurement of trypsin activatable ka/likrein. The changes
induced by trypsin treatment in kallikrein activity in urine and
in perfusate are shown in Table 3. In control perfusions, trypsin
treatment increased urinary kallikrein activity by 167 9%
(range, 136 to 227%): 39 3% of kallikrein in urine was found to
be inactive and trypsin activatable. No change in the ratio of
inactive to total kallikrein was observed during the changes in
PP, drug administration or oxygen-deprivation, indicating that
the changes in total kallikrein paralleled to those in active
kallikrein. In the perfusate, kallikrein activity following trypsin
treatment rose by 238 30% at the end of equilibration period
and by 369 28% at 90 mm of perfusion. Kallikrein activation
was significantly higher than in urine (P < 0.05) and more
important at 90 mm (P < 0.05). The ratio of inactive to total
kallikrein in the perfusate rose significantly with time during all
Fig. 3. Comparison of the effects of an
increase in perfusion pressure and of mannitol
orfurosemide administration. Abbreviations
and symbols are: UV, urinary output; UNaV,
urinary sodium excretion; UKaIIV; urinary
kallikrein excretion; RRS, rate of renin
secretion; , control (N = 11); ft, rise in
perfusion pressure from 80 to 110 mm Hg (N
= 6); H, mannitol administration (N = 6); ,
furosemide administration (N = 6); * < 0.05;
** P < 0.01 compared to control values. UV,
UNaV, and UKaIIV during the 30- to 45-mm
collection period are shown. RRS is the mean
secretion rate during the period from 30 to 60
mm of perfusion.
the experimental procedures, except after oxygen-deprivation,
when it remained constant.
Identification of kinins generated by rat ka/likrein. BK and
LBK were chromatographed on CM-cellulose and eluted with
fractions corresponding to an ammonium acetate concentration
of 0.11 M and 0.21 M, respectively (recovery 85 and 70%). The
kinin generated from bovine kininogen by the kallikrein secret-
ed in urine and perfusate eluted as a single peak of BK (0.11 M
ammonium acetate, recovery 80%). No detectable immunore-
activity was found in the fractions corresponding to LBK.
When urine and perfusate samples were incubated with dog
kininogen, the kinin produced was also found to be BK. After
trypsin treatment urine or perfusate only produced one kinin
which eluted in the fractions corresponding to BK.
Discussion
In the present study, rat kidneys were washed out and
perfused with a blood-free medium without kallikrein. The
kinin-generating activity detected in the perfusate and urine is
therefore of renal origin, We found that the kidney releases
kallikrein not only in urine but also in the perfusate. This was
first shown by Roblero et al [171, but in their study the total
amount of kallikrein secreted in the perfusate was larger than
that secreted in urine. More recently, the same group reported
that the isolated rat kidney releases both active and activatable
kallikrein in urine and perfusate, but twice as much kallikrein in
urine as in perfusate [24]. In our study, the amount of active
kallikrein in the perfusate was less than 10% of that in urine. All
three studies agree that kallikrein is released simultaneously in
urine and perfusate, but they do not agree on the comparative
amounts of kallikrein secreted in the perfusate and urine. The
difference in the results obtained has several possible explana-
tions: (1) the fact that kinin generating activity was measured in
our study by RIA, which is more specific and more sensitive
than the previously used bioassay. (2) In Roblero's and Corth-
orn's studies, kidneys were perfused in an open circuit whereas
here the perfusate was recirculated continuously in a closed
circuit. In our circuit, kallikrein can be filtered, inactivated in
the tubules, and/or excreted in urine [25]. However, assuming a
GFR of 0.4 ml mint, a kallikrein concentration in the perfus-
ate of 0.09 ng BK ml min', and a total perfusate volume
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Table 3. Effect of trypsin on kallikrein activity in urine and perfusatea
No Trypsin Inactive/total
trypsin treatment kallikrein, %
Urine
Control (11) 100 167 9 39 3
High PP (6) 100 152 5 34 2
Low PP (6) 100 158 6 36 3
Furosemide (6) 100 167 6 40 2
Isoproterenol (6) 100 171 6 41 2
Oxygen-deprived (6) 100 166 7 38 3
Perfusate
Control (6) 0 mm
90 mm
100
100
238
369
30
28b
54 7
72 2c
Oxygen-deprived (6) 0 mm
90 mm
100
ioo
262
251
12
21"
62 2
58 3d
a Values are expressed as percentages in the changes of activity after
trypsin treatment. Total kallikrein is the sum of active and inactive
kallikrein. Kallikrein activity was measured on urine collected during
the last 60 mm of perfusion. Kallikrein activity in perfusate was
measured at 0 and 90 mm after the equilibration period (see Results).
Numbers in parentheses are numbers of experiments.
b P < 0.05.
P < 0.01 compared to 0 mm values.
d P < 0.01 compared to the corresponding control values.
of 80 ml, it can be calculated that the maximal amount of
kallikrein which could have been filtered during the 90 mm of
perfusion is less than half of the total amount of kallikrein
present in the perfusate at the end of perfusion. Therefore, even
11 kallikrein had not been filtered, the amount of kallikrein
secreted in the perfusate would still have been much below that
secreted in urine. (3) It is also possible that in a closed circuit, a
renal inhibitor of kallikrein [26] is released and accumulated in
the perfusate.
Recently, Corthorn et a! [27] demonstrated that in human
urine 25 to 75% of kallikrein is inactive and trypsin activatable.
We also show here that trypsin activatable kallikrein is released
by the rat kidney. Roughly half of the kallikrein present in urine
or in perfusate is inactive form. In urine the changes in total
kallikrein were always parallel to those in active ka!likrein. In
the perfusate the percentages of inactive kallikrein rose with the
time of perfusion, but the amount of total kallikrein released
remained five times lower than that secreted in urine. Even if a
small amount of enzyme is actually released in vascular space
or in lymph, its biological role is certainly limited by the
presence of several circulating potent inhibitors of kallikrein
[28]. Inactive forms of kallikrein were also observed on the
basolateral membrane of kidney tubule [29] and may be re-
leased in blood. When urinary kallikrein activity was altered by
changes in PP, we found no changes in active or total kallikrein
release in the perfusate. Contrarily to Roblero, Croxatto, and
Albertini [30], who reported that kallikrein activity increased in
the perfusate after administration of furosemide, no regulation
of kallikrein secretion in the perfusate, even by furosemide, was
observed in our study. Only when the oxygen supply to the
kidney was discontinued did kallikrein secretion increase in the
perfusate while decreasing in urine. This effect of anoxia can
probably be explained by the damage which occurred in the
tubular cells and the consequent release of intracellular kalli-
krein. It is therefore not impossible that, when the perfusate
Table 4. Renin secretion in perfusate and urinea
Perfusate renin secretion Urinary renin excre-
zgAI hr min' tion p.g Al hr
Control (11) 1.262 0.096 4.237 0.463
High PP (6) 0.369 0.041" 6.792 0.387"
Low PP (6) 1.715 0.219b 1.233 0.069c
Mannitol (6) 0.796 0,111" 2.766 1.061
Furosemide (6) 2.218 0.311" 6.022 0.953
Isoproterenol (6) 3.527 0.138" 8.069 0.838"
Oxygen-deprived (6) 0.470 0.04 I' 1.610 0.262"
a Renin in perfusate is expressed in the rate of renin secretion for the
last 60 mm of perfusion (see Results). Renin in urine is expressed in
igAI generated per hour of incubation by the total renin present in
urine collected during this period. Numbers in parentheses are numbers
of experiments.
b P < 0.05.
"P < 0.01 compared to control values.
contains oxygen, the presence of kallikrein is at least partly due
to its release into the perfusate by damaged cells. Damage to the
distal tubules during in vitro kidney perfusion has been reported
by Alcorn et al [311.
In kidneys perfused at a constant pressure, kallikrein secre-
tion in urine was initially high and fell with time. The mecha-
nism of this decrease is unknown. Sudden changes in vascular
pressure or in blood supply, or the disappearance of extrarenal
factors, like blood or renal nerves might perhaps initiate a
kallikrein secretion by the kidney. Ischemic damage of the
kidney does not seem to account for the high initial secretion of
kallikrein in urine, since anoxia reduces rather than enhances
kallikrein secretion in urine. This effect of anoxia suggests that
the release of kallikrein in urine is an active, oxygen-dependent
process.
Kallikrein secretion increased markedly when the PP was
raised and fell when it was lowered. These changes in PP have
the opposite effects on renin secretion. Isolated perfused kidney
lacks autoregulation and changes in the PP induce changes in
RPF, GFR, UV and UNaV. Therefore, it is not clear which
factor was primarily responsible for the present changes in
kallikrein secretion. A positive correlation between urinary
kallikrein excretion and renal artery pressure or renal blood
flow has been documented in the dog [13, 32], and humans [33].
It has also been reported that kallikrein excretion in vivo is
positively correlated with UV and/or UNaV [6, 7, 34], and that
the diuretic effects of water loading [35], and of the administra-
tion of saline [7] or diuretics [36] enhance kallikrein excretion.
Therefore we investigated the effects of raising the urinary
output of water and sodium at a constant PP on this secretion.
Mannitol and furosemide induced an increase in UV and UNaV
similar to that observed after raising the PP but did not
significantly change kallikrein secretion. Changes in the compo-
sition of distal urine are therefore not involved in regulating
kallikrein release. Recently, Bonner et al [37] demonstrated that
acute administration of mannitol induced diuresis and transient-
ly increased urinary kallikrein excretion in rats, attributed to a
wash-out phenomenon induced by the enhanced urine flow.
However, our negative results after mannitol and furosemide
administration indicate that the marked increase in kallikrein
secretion observed after raising the PP was certainly not
exclusively due to a wash-out phenomenon. The increase in
64 Misumi et a!
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